John Lykoudis (Greek: Ιωάννης Λυκούδης; 1910 in Missolonghi – 1980) was a Greek physician and politician. He treated patients who had peptic ulcer disease with antibiotics long before it was commonly recognized that bacteria were a dominant cause for the disease.[1] He became mayor of Missolonghi in 1951, serving until 1959.[2]
Career
editAfter treating himself for peptic ulcer disease with antibiotics in 1958 and finding the treatment effective, Lykoudis began treating patients with antibiotics. After experimenting with several combinations of antibiotics he eventually arrived at a combination which he termed Elgaco and which he patented in 1961. It has been estimated that he treated more than 30,000 patients.
In his time he had great difficulties in persuading the Greek medical establishment about the effectiveness of the treatment. He was given a fine of 4000 drachmas by a disciplinary committee, and indicted in the Greek courts. He was unable to get an article published in the Journal of the American Medical Association and was not able to get the established pharmaceutical companies sufficiently interested in the treatment.[1]
See also
editLiterature
edit- Basil Rigas; Chris Feretis; Efstathios D Papavassiliou (1 November 1999). "John Lykoudis: an unappreciated discoverer of the cause and treatment of peptic ulcer disease". The Lancet. 354 (9190): 1634–1635. doi:10.1016/S0140-6736(99)06034-1. ISSN 0140-6736. PMID 10560691. Wikidata Q33880179.
- Michael Phillips (1 January 2000). "John Lykoudis and peptic ulcer disease". The Lancet. 355 (9198): 150. doi:10.1016/S0140-6736(05)72070-5. ISSN 0140-6736. PMID 10675202. Wikidata Q50246020.
References
edit- ^ a b Helicobacter pioneers : firsthand accounts from the scientists who discovered helicobacters, 1892-1982. Marshall, Barry J., 1951-. Victoria, Australia: Blackwell. 2002. ISBN 978-0-86793-035-1. OCLC 50445822.
{{cite book}}: CS1 maint: others (link) - ^ ""Οι Δήμαρχοι του Μεσολογγίου", το βιβλίο του Διονύση Μπερερή". iAitoloakarnania (in Greek). 2019-05-17. Retrieved 2021-02-01.